Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy

Clinica Chimica Acta

Volumn 416, Issue , 2013, Pages 5-10

  Wotschofsky, Zofia ^a,b   Busch, Jonas ^a   Jung, Monika ^a   Kempkensteffen, Carsten ^a   Weikert, Steffen ^a   Schaser, Klaus D ^a   Melcher, Ingo ^a   Kilic, Ergin ^a   Miller, Kurt ^a   Kristiansen, Glen ^c   Erbersdobler, Andreas ^d   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Clear cell renal cell carcinoma; MicroRNAs; Prognostic markers; Recurrence risk prediction

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 141; MICRORNA 155; MICRORNA 184; MICRORNA 200C; MICRORNA 210; MICRORNA 224; MICRORNA 514; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; NEPHRECTOMY; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; UNIVARIATE ANALYSIS; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; POLYMERASE CHAIN REACTION; PROGNOSIS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871028123     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.11.010     Document Type: Article

References (34)

1. Eichelberg C., Junker K., Ljungberg B., Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55:851-863.
2. Stewart G.D., O'Mahony F.C., Powles T., Riddick A.C., Harrison D.J., Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma?. Nat Rev Urol 2011, 8:255-265.
3. Sun M., Shariat S.F., Cheng C., et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60:644-661.
4. Schaefer A., Stephan C., Busch J., Yousef G.M., Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010, 7:286-297.
5. Catto J.W., Alcaraz A., Bjartell A.S., et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011, 59:671-681.
6. Fendler A., Stephan C., Yousef G.M., Jung K. MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem 2011, 57:954-968.
7. White N.M., Fatoohi E., Metias M., Jung K., Stephan C., Yousef G.M. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol 2011, 8:75-84.
8. Gottardo F., Liu C.G., Ferracin M., et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007, 25:387-392.
9. Nakada C., Matsuura K., Tsukamoto Y., et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 2008, 216:418-427.
10. Jung M., Mollenkopf H.J., Grimm C., et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009, 13:3918-3928.
11. Petillo D., Kort E.J., Anema J., Furge K.A., Yang X.J., Teh B.T. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009, 35:109-114.
12. Juan D., Alexe G., Antes T., et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010, 75:835-841.
13. Dall'Oglio M.F., Coelho R.F., Leite K.R., Sousa-Canavez J.M., Oliveira P.S., Srougi M. Gene expression profile of renal cell carcinoma clear cell type. Int Braz J Urol 2010, 36:410-418.
14. Fridman E., Dotan Z., Barshack I., et al. Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 2010, 12:687-696.
15. Youssef Y.M., White N.M., Grigull J., et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 2011, 59:721-730.
16. Heinzelmann J., Henning B., Sanjmyatav J., et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011, 29:367-373.
17. Slaby O., Jancovicova J., Lakomy R., et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 2010, 29:90.
18. Slaby O., Redova M., Poprach A., et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012, 51:707-716.
19. Wotschofsky Z., Meyer H.A., Jung M., et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem 2011, 417:233-241.
20. Sobin L.H., Wittekind C. TNM classification of malignant tumours 2002, 193-195. Wiley-Liss, New York. 6th ed.
21. Jung M., Schaefer A., Steiner I., et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010, 56:998-1006.
22. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
23. Kubista M., Andrade J.M., Bengtsson M., et al. The real-time polymerase chain reaction. Mol Aspects Med 2006, 27:95-125.
24. Steyerberg E.W., Harrell F.E., Borsboom G.J., Eijkemans M.J., Vergouwe Y., Habbema J.D. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001, 54:774-781.
25. White N.M., Bao T.T., Grigull J., et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011, 186:1077-1083.
26. Zhou L., Chen J., Li Z., et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One 2010, 5:e15224.
27. Bovelstad H.M., Nygard S., Borgan O. Survival prediction from clinico-genomic models-a comparative study. BMC Bioinformatics 2009, 10:413.
28. Kanaan Z., Rai S.N., Eichenberger M.R., et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat 2012, 33:551-560.
29. Lewis A.P., Jopling C.L. Regulation and biological function of the liver-specific miR-122. Biochem Soc Trans 2010, 38:1553-1557.
30. Streicher K.L., Zhu W., Lehmann K.P., et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012, 31:1558-1570.
31. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011, 39:D152-D157.
32. Machin D., Cheung Y.B., Parmar M.K.B. Survival analysis: a practical approach 2006, 207-221. Wiley & Sons, Ltd., Chichester, U.K. 2nd ed.
33. Peduzzi P., Concato J., Feinstein A.R., Holford T.R. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995, 48:1503-1510.
34. Kawada T. The appropriate number of endpoints to keep validity for Cox proportional hazard analysis. Int J Cardiol 2011, 153:110-111.